(NASDAQ: CTSO) Cytosorbents's forecast annual revenue growth rate of 12.61% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.23%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.63%.
Cytosorbents's revenue in 2024 is $37,159,990.On average, 3 Wall Street analysts forecast CTSO's revenue for 2024 to be $2,151,221,753, with the lowest CTSO revenue forecast at $2,042,199,230, and the highest CTSO revenue forecast at $2,249,576,071. On average, 3 Wall Street analysts forecast CTSO's revenue for 2025 to be $2,537,291,026, with the lowest CTSO revenue forecast at $2,421,573,660, and the highest CTSO revenue forecast at $2,708,417,742.
In 2026, CTSO is forecast to generate $2,877,421,703 in revenue, with the lowest revenue forecast at $2,848,846,154 and the highest revenue forecast at $2,905,997,252.